A phase 3 trial found that Eli Lilly's tirzepatide significantly reduced the risk of progression to Type 2 diabetes in prediabetic adults over a three-year period. Nearly 99% of individuals treated ...

A recent study that found there has been a massive increase in type 2 diabetes cases worldwide since 1990 is an indication ...

Has something changed regarding Eli Lilly or Regeneron's thesis, or is the recent dip an excellent opportunity to invest in ...

Eli Lilly has reported comprehensive outcomes from the SURMOUNT-1 study of tirzepatide (Zepbound and Mounjaro) for treating ...

The weight loss drugs Ozempic and Wegovy may be beneficial for people struggling with alcohol addiction, a study published ...

New research shows that weight loss medications can stop the progression of prediabetes. Experts don’t all agree on such a ...

Eli Lilly said on Wednesday its weight-loss drug helped nearly 99% of patients remain diabetes-free after three years of ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Amgen has rebuffed claims made by an analyst suggesting that its obesity drug MariTide is associated with reductions in bone ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

Since semaglutide was approved by the FDA for weight loss under the brand name Wegovy in 2021, GLP-1 medications—originally ...

Medications such as semaglutide (branded as Ozempic and Wegovy) and tirzepatide (branded as Mounjaro and Zepbound) work by ...